Business Context and Reporting Period
Revolution Medicines, Inc. (RVMD), a Delaware corporation, filed this Form 8-K on March 4, 2021. The report addresses corporate governance updates and executive compensation adjustments for the fiscal year ended December 31, 2020.
Key Financial Metrics
This filing does not report operational financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation updates and bylaw amendments.
| Executive | 2020 Total Compensation | 2020 Non-Equity Incentive |
|---|---|---|
| Mark A. Goldsmith (CEO) | $2,388,211 | $406,000 |
| Steve Kelsey (President, R&D) | $1,262,469 | $273,700 |
| Margaret Horn (COO & General Counsel) | $1,257,950 | $273,700 |
Material Changes
- Executive Compensation Update: The filing updates the Summary Compensation Table from the Company's Form S-1 Registration Statement to include 2020 performance bonuses for Named Executive Officers (NEOs) that were not determined at the time of the S-1 effectiveness.
- Bylaw Amendment: The Board amended the Company's Bylaws to establish the federal district courts of the United States as the exclusive forum for claims arising under the Securities Act of 1933, unless the Company consents in writing to an alternative forum.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future business performance. The primary risk disclosure relates to the new exclusive forum provision, which may limit the ability of shareholders to bring claims in state or other federal courts.
Investor Verification Checklist
- Verify the total 2020 compensation figures for NEOs against the updated Summary Compensation Table in this filing.
- Review the attached Amended and Restated Bylaws (Exhibit 3.1) to understand the specific legal implications of the exclusive federal forum provision.
- Confirm that no other financial data in the previously filed Form S-1 has changed, as stated in the filing.